Zacks: Brokerages Set $6.55 Price Target for Theratechnologies Inc. (NASDAQ:THTX)
Theratechnologies Inc. (NASDAQ:THTX) has received a consensus broker rating score of 1.50 (Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and three have issued a strong buy recommendation on the company. Theratechnologies’ rating score has improved by 10.2% from three months ago as a result of various analysts’ ratings changes.
Brokerages have set a 12 month consensus price target of $6.55 for the company and are anticipating that the company will post $0.01 EPS for the current quarter, according to Zacks. Zacks has also assigned Theratechnologies an industry rank of 41 out of 254 based on the ratings given to its competitors.
Several equities analysts recently weighed in on the stock. Zacks Investment Research raised shares of Theratechnologies from a “sell” rating to a “hold” rating in a research note on Wednesday. Canaccord Genuity cut their price target on Theratechnologies from $12.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, April 15th. Finally, Mackie reaffirmed a “buy” rating and set a $5.80 price target on shares of Theratechnologies in a report on Tuesday, February 25th.
NASDAQ:THTX opened at $1.87 on Friday. Theratechnologies has a 1-year low of $1.33 and a 1-year high of $5.73. The company has a current ratio of 2.18, a quick ratio of 1.53 and a debt-to-equity ratio of 2.83. The firm has a fifty day simple moving average of $2.06 and a 200 day simple moving average of $2.41. The stock has a market capitalization of $147.01 million, a PE ratio of -9.35 and a beta of 1.43.
Theratechnologies (NASDAQ:THTX) last released its earnings results on Tuesday, April 14th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.05). Theratechnologies had a negative net margin of 24.77% and a negative return on equity of 59.18%. The firm had revenue of $15.72 million during the quarter, compared to the consensus estimate of $18.58 million. On average, equities analysts predict that Theratechnologies will post -0.02 earnings per share for the current fiscal year.
Theratechnologies Company Profile
Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States.
Featured Story: Stochastic Momentum Index (SMI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.